Acadia Healthcare Company, Inc. (NASDAQ:ACHC)‘s stock had its “positive” rating reissued by investment analysts at UBS AG in a research report issued to clients and investors on Monday, July 31st, www.benzinga.com reports. They presently have a $60.00 price target on the stock, up from their previous price target of $54.00. UBS AG’s target price would suggest a potential upside of 14.55% from the stock’s current price.
A number of other research analysts have also recently issued reports on the company. Mizuho lifted their target price on Acadia Healthcare from $57.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 28th. William Blair assumed coverage on Acadia Healthcare in a research report on Tuesday, July 18th. They issued an “outperform” rating on the stock. BidaskClub upgraded Acadia Healthcare from a “hold” rating to a “buy” rating in a research report on Saturday, July 1st. Zacks Investment Research upgraded Acadia Healthcare from a “hold” rating to a “buy” rating and set a $53.00 target price on the stock in a research report on Wednesday, June 28th. Finally, KeyCorp restated an “overweight” rating and set a $51.00 price target on shares of Acadia Healthcare in a report on Thursday, June 1st. Five equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $59.21.
Acadia Healthcare (NASDAQ ACHC) opened at 52.38 on Monday. Acadia Healthcare has a one year low of $32.54 and a one year high of $54.73. The firm has a market capitalization of $4.60 billion, a price-to-earnings ratio of 575.60 and a beta of 1.15. The firm’s 50-day moving average is $50.30 and its 200 day moving average is $44.67.
Acadia Healthcare (NASDAQ:ACHC) last released its earnings results on Thursday, July 27th. The company reported $0.66 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.01. Acadia Healthcare had a return on equity of 8.69% and a net margin of 0.30%. The firm had revenue of $715.90 million for the quarter, compared to analysts’ expectations of $717.38 million. During the same quarter in the previous year, the business posted $0.73 earnings per share. The business’s revenue for the quarter was down 5.4% on a year-over-year basis. Analysts forecast that Acadia Healthcare will post $2.45 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was first published by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://transcriptdaily.com/2017/08/13/acadia-healthcares-nasdaqachc-positive-rating-reiterated-at-ubs-ag-updated.html.
In other news, Director Reeve B. Waud sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $45.09, for a total transaction of $2,254,500.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director William Grieco sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, June 16th. The stock was sold at an average price of $45.42, for a total value of $90,840.00. Following the transaction, the director now directly owns 47,013 shares in the company, valued at $2,135,330.46. The disclosure for this sale can be found here. Over the last three months, insiders sold 2,136,347 shares of company stock worth $105,383,249. Insiders own 11.10% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. raised its position in shares of Acadia Healthcare by 43.9% in the first quarter. Russell Investments Group Ltd. now owns 221,649 shares of the company’s stock worth $9,664,000 after buying an additional 67,665 shares during the last quarter. Emerald Advisers Inc. PA increased its stake in shares of Acadia Healthcare by 2.3% in the first quarter. Emerald Advisers Inc. PA now owns 85,198 shares of the company’s stock valued at $3,715,000 after buying an additional 1,876 shares during the period. Parametrica Management Ltd bought a new stake in shares of Acadia Healthcare during the first quarter valued at about $291,000. UBS Asset Management Americas Inc. increased its stake in shares of Acadia Healthcare by 21.6% in the first quarter. UBS Asset Management Americas Inc. now owns 332,355 shares of the company’s stock valued at $14,491,000 after buying an additional 59,001 shares during the period. Finally, Sheets Smith Wealth Management increased its stake in shares of Acadia Healthcare by 11.1% in the second quarter. Sheets Smith Wealth Management now owns 9,094 shares of the company’s stock valued at $449,000 after buying an additional 910 shares during the period.
Acadia Healthcare Company Profile
Acadia Healthcare Company, Inc is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities.
Receive News & Ratings for Acadia Healthcare Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.